Rhythm Pharmaceuticals Receives Positive CHMP Opinion for &#

BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announc...

Related Keywords

Boston , Massachusetts , United States , United Kingdom , Great Britain , Philip Beales , David Meeker , University College London , European Commission , Drug Administration , Great Britain Medicines Healthcare Products Regulatory Agency , Rhythm Pharmaceuticals , Nasdaq , Health Technology Assessment , Rhythm Pharmaceuticals Inc , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , Institute Of Child Health , Medicinal Products , Human Use , Chief Executive Officer , Child Health , Healthcare Products Regulatory Agency , Rhythm Engine ,